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theBACKGROUND Health care–associated infections (HAIs) are the most common noncardiac complications after cardiac
surgery andare associatedwith increasedmorbidity andmortality. Current informationabout their economic burden is limited.
OBJECTIVES This research was designed to determine the cost associated with major types of HAIs during the ﬁrst
2 months after cardiac surgery.
METHODS Prospectively collected data from a multicenter, observational study of the Cardiothoracic Surgery Clinical
Trials Network, in which patients were monitored for infections for 65 days after surgery, were merged with related
ﬁnancial data routinely collected by the University HealthSystem Consortium. Incremental length of stay (LOS) and cost
associated with HAIs were estimated using generalized linear models, with adjustments for patient demographics, clinical
history, baseline laboratory values, and surgery type.
RESULTS Among 4,320 cardiac surgery patients (mean age: 64  13 years), 119 (2.8%) experienced a major HAI during
the index hospitalization. The most common HAIs were pneumonia (48%), sepsis (20%), and Clostridium difﬁcile colitis
(18%). On average, the estimated incremental cost associated with a major HAI was nearly $38,000, of which 47% was
related to intensive care unit services. The incremental LOS was 14 days. Overall, there were 849 readmissions; among
these, 8.7% were attributed to major HAIs. The cost of readmissions due to major HAIs was, on average, nearly threefold
that of readmissions not related to HAIs.
CONCLUSIONS Hospital cost, LOS, and readmissions are strongly associated with HAIs. These associations suggest the
potential for large reductions in costs if HAIs following cardiac surgery can be reduced. (Management Practices and the
Risk of Infections Following Cardiac Surgery; NCT01089712) (J Am Coll Cardiol 2015;65:15–23) © 2015 by the American
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16P atients undergoing cardiac surgery areat risk for major postoperative infec-tions (1–3), which carry devastat-
ing, if not fatal, clinical consequences and
substantial costs, as reﬂected by prolonged
hospitalizations and more frequent readmis-
sions (4,5). Reducing the risk for health care–
associated infections (HAIs) is a key priority
for improving surgical care. HAIs are of
increasing concern given that patients under-
going cardiac surgery are older and have mul-
tiple comorbidities, which further increaseSEE PAGE 24their infection risk. Some HAIs have recently
decreased due to the identiﬁcation and suc-
cessful implementation of best practices.
For example, in the United States, the rateof catheter-related bloodstream infections in the
intensive care unit (ICU), decreased by 46% between
2008 and 2012, and the rate of surgical-site infections
after cardiac procedures decreased by 30% over the
same period (6–8). On the other hand, other important
infections, such as pneumonia and sepsis, remain
common, and other, previously uncommon infec-
tions, such as Clostridium difﬁcile colitis, have been
increasing in recent years (9,10). Although signiﬁ-
cant achievements have been made, there remains a
nearly 5% risk for major post-operative infections in
patients in the ﬁrst 2 months following cardiac sur-
gery, which is associated with a 10-fold higher risk
for mortality (10).
Health care payers and policymakers have devel-
oped mechanisms aimed at preventing HAIs, in-
cluding denial of reimbursement for the extra cost
of treating HAIs considered preventable, manda-
tory public reporting of institutions’ HAI rates, and
transparency regarding the level of adherence to
national quality measures (11,12). However, detailed
data regarding the economic impact of postoperative
complications, particularly complications related to
infectious processes, remain scarce. Measuring the
economic impact of HAIs—especially in the context of
invasive cardiac procedures, during which a patient is
particularly vulnerable to infection—is essential for
understanding the contribution of HAIs to rising
health care costs and for developing sustainable
approaches to preventing infection.thors report that they have no relationships relevant to the cont
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received April 23, 2014; revised manuscript received SeptemberResearch on the cost of HAIs has primarily focused
on speciﬁc infection sites or pathogens, or has been
limited to the index hospitalization. Few studies
capture the full economic impact of a broad range of
possible HAIs or the impact of these infections on
hospital readmissions (13,14). Those studies that have
addressed the economic impact of a broader spectrum
of HAIs in cardiac surgery patients have typically
relied on billing datasets (5,15), which have important
limitations in identifying HAIs due to their reli-
ance on International Classiﬁcation of Diseases-Ninth
Revision (ICD-9) infection codes (16,17). Only one in
four HAIs, as detected by ICD-9 codes, meets standard
Centers for Disease Control and Prevention (CDC)/
National Healthcare Safety Network deﬁnitions and
criteria (17). Billing data alone may lack the degree of
clinical detail needed for adequately adjusting for
patients’ baseline clinical status. This study, how-
ever, combines two data sources: 1) clinical data
from a prospective, multicenter, observational cohort
study that evaluated the occurrence of major HAIs;
and 2) economic data obtained from the University
HealthSystem Consortium (UHC), and it addresses the
economic burden of the major types of HAIs acquired
within 65 days after cardiac surgery.
METHODS
DATA SOURCES. Between February 2010 and
October 2010, a prospective, multicenter, observa-
tional study (n ¼ 5,158) was conducted by the
National Heart, Lung, and Blood Institute–sponsored
Cardiothoracic Surgical Trials Network (CTSN) (trial
investigators are listed in the Online Appendix) to
assess the occurrence of HAIs after cardiac surgery.
The study protocol was approved by the institutional
review board at each participating clinical site and
was compliant with the Health Insurance Portability
and Accountability Act. All adult ($18 years of age)
cardiac surgery patients without active infections on
admission were eligible to participate. Recruitment of
all eligible patients continued until a pre-speciﬁed
number of infectious events was reached. Data
collected from this cohort were used in the present
study and included demographics, body habitus,
baseline laboratory results, comorbid conditions,
type of surgery performed, infections, and read-
missions within 60  5 days of surgery. Patients had aents of this paper to disclose.
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17follow-up visit or phone call at 30 and 60  5 days
after surgery for the collection of information about
their health status and hospital readmission history.
Discharge summaries and medical records were
obtained and reviewed to determine the reason for
the readmission in patients hospitalized at out-
of-network institutions.
An independent committee of infectious-diseases
experts, using deﬁnitions adapted from the CDC/
National Healthcare Safety Network, reviewed and
adjudicated all major postoperative infections. The
last infectious event was reviewed in June 2012. The
quality and completeness of the data were monitored
as described elsewhere (10). Clinical data collected in
the study were linked to patient-level economic data
obtained directly from the sites or from theUHC,which
is an alliance of U.S. academic medical centers. Data
linkage was done using a combination of variables,
including sex, date of birth, procedure date and type,
admission and discharge dates, and hospital identiﬁ-
cation number. In addition to those from the index
hospitalization, data up to 65 days after surgery were
extracted from the UHC database, including cost data,
revenue codes, and ICD-9 codes. Costs were obtained
bymultiplying charges by the cost center–speciﬁc cost-
to-charge ratios for each institution. Such ratios are
based on the annual Medicare cost reports submitted
by individual hospitals. This method of approximating
cost is widely used and provides reasonably accurate
estimates of actual costs (18). From out-of-network
readmissions (readmissions in hospitals not partici-
pating in the study), only length of stay (LOS) was
available. Because the CTSN study protocol did not
include readmissions for rehabilitation and emer-
gency department visits, these types of events were
ﬁltered from UHC using the ICD-9 code for rehabilita-
tion, the revenue code for emergency department
visits, and direct veriﬁcation with the clinical site.
Of the 10 centers participating in the CTSN study
(9 in the United States and 1 in Canada), only the U.S.
centers were included in this study, to use more
homogeneous cost data. Of 4,614 patients undergoing
cardiac surgery in the United States, data from 4,320
(93.6%) were matched to their corresponding ﬁnan-
cial records. Data from patients who could not be
matched (6.4%) were distributed across all hospitals;
these patients did not differ in baseline characteris-
tics, including demographics, laboratory values, and
comorbidities, from patients who could be matched.
Data from unmatched patients were excluded from
the analysis.
ENDPOINTS AND ANALYSIS. The endpoints for
this study were incremental hospital LOS and infec-
tion cost.Cost dur ing the index hosp i ta l i zat ion . Direct
hospital costs associated with major HAIs were
calculated separately for the index hospitalization
and for subsequent readmissions. For the index
hospitalization, extra costs associated with major
HAIs were estimated using a generalized linear model
(GLM), with a log-link function and a gamma distri-
bution. This method adjusts for patient-related con-
founders while accounting for the nature of cost data,
which are often skewed to the right with hetero-
skedasticity. Factors found to be associated with cost
(at p < 0.15) were assessed in the multivariate anal-
ysis. To generate the ﬁnal multivariate model, we
removed statistically nonsigniﬁcant variables and
reﬁtted the model until all variables in the model had
a p value of 0.05 or less. The ﬁnal model included the
baseline factors age; sex; race/ethnicity; body mass
index; white blood cell count; hemoglobin and
creatinine concentrations; ejection fraction; sta-
tuses of pulmonary disease, diabetes, hypertension,
hypercholesterolemia, congestive heart failure, and
peripheral vascular disease; history of cerebrovascu-
lar accident, cardiac surgery, and use of corticoste-
roids; and type of procedure and its duration.
Covariates and parameter estimates are shown in
Online Table 1.
The incremental cost—the additional cost associ-
ated with major HAIs—was then calculated using the
recycled prediction method (19). Put simply, via the
parameters estimated through the GLM approach, we
estimated the incremental cost due to major HAIs by
varying the infection status while the other parame-
ters were held constant. The mean difference of the
two predictions—with and without major HAI—
provided the incremental cost attributable to major
HAI. Standard errors and conﬁdence intervals (CIs)
were derived by 1,000 bootstrap resampling runs. In
each run, we randomly drew patients with replace-
ment from each group separately (infection and
noninfection), thereby creating 1,000 pairs of boot-
strap samples. GLM modeling was repeated for each
pair to get the estimated predicted mean differences.
By ordering all of the 1,000 random estimates, the
2.5 and 97.5 percentiles were used as the conﬁdence
limits.
Cost of rehosp i ta l i zat ions . Hospital readmissions
were stratiﬁed into two categories, depending on
whether their occurrence was attributable to HAI or
not. Descriptive statistics were then calculated. Cost
data were available only for readmissions to hospitals
participating in the CTSN study.
Length of stay . Duration of hospital stay was ob-
tained from all index hospitalizations and all read-
missions. For the index hospitalizations, incremental
TABLE 1
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18LOS was calculated using GLM with a log-link and a
gamma distribution, and adjustment for the same
variables used in the cost model. For rehospitaliza-
tions, the incremental LOS associated with infections
was considered equivalent to the mean LOS of the
rehospitalizations attributed to infections.
All analyses were conducted utilizing SAS
version 9.2 (SAS Institute Inc., Cary, North Carolina).
Descriptive analyses were performed using the
Wilcoxon-Mann-Whitney test for all continuous var-
iables, and using the chi-square or Fisher exact test
for all categorical variables.Patients’ Baseline Characteristics
Major Infection
(n ¼ 119)
Control
(n ¼ 4,201) p Value*
hics
65.8  14.1 64.3  13.4 0.23
83 (69.8) 2,771 (66.0) 0.39
88 (74.0) 3,455 (82.2) 0.02
/m2 28.6 (25.1–34.2) 28.2 (25.1–32.2) 0.40
y analysis
unt, cells  103/ml 7.3 (5.8–8.6) 6.9 (5.7–8.3) 0.21
ne, mg/dl 1.2 (0.9–1.6) 1.0 (0.8. 1.2) <0.001
obin, g/dl 12.4 (11.0–13.9) 13.3 (12.0–14.5) 0.0004
s
ascular
stive heart failure 58 (48.7) 1,104 (26.3) <0.001
ction fraction, % 50 (35.0–60.0) 55 (48.0–60.0) 0.0008
cardiac surgery 42 (35.3) 819 (19.5) <0.001
rovascular accident 18 (15.1) 400 (9.5) 0.04
eral vascular disease 16 (13.5) 426 (10.1) 0.24
osteroid use 12 (10.1) 123 (2.9) <0.0001
orbidities
tension 99 (83.2) 3,138 (74.7) 0.04
tes 31 (26.1) 941 (22.4) 0.35
disease 24 (20.2) 606 (14.4) 0.08
aracteristics
, h 5.4 (4.0–6.9) 4.3 (3.5–5.3) <0.0001
my 112 (94.1) 3,779 (90.0) 0.13
0.0003
ve 66 (55.4) 3,021 (71.9)
t 46 (38.7) 1,068 (25.4)
ent 7 (5.9) 112 (2.7)
re <0.0001
ed valve 30 (25.2) 1,316 (31.3)
ed CABG 20 (16.8) 1,213 (28.9)
plantation or VAD 17 (14.3) 93 (2.2)
þ valve 15 (12.6) 492 (11.7)
cic aortic 8 (6.7) 213 (5.1)
29 (24.4) 874 (20.8)
ean  SD, n (%), or median (interquartile range). *Chi-square test was conducted for
ategorical variables, and Wilcoxon-Mann-Whitney test was conducted for comparing
variables.
dy mass index; CABG ¼ coronary artery bypass grafting surgery; VAD ¼ ventricular
e implantation or explantation; WBC ¼ white blood cell.RESULTS
CHARACTERISTICS OF THE STUDY POPULATION.
Among the 4,320 patients in this cohort, the mean age
was 64  13 years; 66% were male; and the mean body
mass index was 28  6 kg/m2 (Table 1). Among pa-
tients with major HAIs, there were higher prevalences
of prior cardiac surgery, congestive heart failure, hy-
pertension, and history of stroke. Patients with major
HAIs had lower ejection fractions and lower levels of
hemoglobin, and marginally higher levels of creati-
nine. Major infections were more common in patients
who had longer, urgent, or emergent surgeries.
Transplant recipients and patients who received a
ventricular assist device (VAD) were more likely to
have developed major HAIs during the index hospi-
talization compared with patients who underwent
other types of cardiac procedures (15.4% vs. 2.4%;
p <0.0001).
During the course of the index hospitalization and
of ensuing readmissions, 250 major HAIs developed
in 194 patients (4.5% of the cohort). Of these, 119
patients (2.7%) acquired one or more major HAIs
during their index hospitalization, and 88 patients
(2%) had a major HAI associated with their read-
mission (Table 2). Among patients with HAI-related
readmissions, 9 (10.2%) had received a transplant
or VAD during the index hospitalization. The
most common type of major HAI was pneumonia,
followed by bloodstream infection, C. difﬁcile colitis,
and surgical-site infections.
COST OF THE INDEX HOSPITALIZATION. On average,
patients who developed a major HAI during the index
hospitalization had a longer LOS than did patients
who did not (mean: 33 vs. 9 days). Patients with
infections also had a more costly hospital stay than
did noninfected patients (mean: [2010 U.S. dollars]
$110,155 vs. $31,530). During the course of a hospi-
talization, the level of resource utilization changed
daily. For patients without major HAIs, the mean cost
of care per day peaked at the ﬁrst 2 days around
$5,000, and then declined sharply, leveling off at
about $2,000 per day within a week (Central
Illustration). In contrast, in patients who acquired a
major HAI, the mean cost per day remained sustained
for a longer period of time, gradually declining in
roughly 3 weeks to a level comparable to that of
noninfected patients. After adjustment for patient-
related confounders, the additional cost per major
HAI amounted to almost $38,000 (Table 3). On
average, the LOS of patients who had a major HAI was
14 days longer than that of patients who did not ac-
quire a major HAI. The adjusted incremental costs of
TABLE 2 Types of Major Infection During Index Hospitalization and Rehospitalization
(N ¼ 4,320)
Type of Infection
Index Hospitalization Rehospitalization
No. of
Events
Patients,
n (%)
No. of
Events
Patients,
n (%)
Pneumonia 73 72 (1.67) 33 33 (0.76)
Bloodstream infection 31 28 (0.65) 14 14 (0.32)
Clostridium difﬁcile 28 28 (0.65) 17 15 (0.35)
Deep incision surgical site infection*
Chest 6 6 (0.15) 18 17 (0.44)
Groin 2 2 (0.05) 5 5 (0.13)
Mediastinitis 5 5 (0.12) 5 5 (0.12)
Myocarditis or pericarditis 3 3 (0.07) 2 2 (0.05)
Empyema 2 2 (0.05) 1 1 (0.02)
Pocket infection† 1 1 (1.27) 1 1 (1.27)
Endocarditis 0 0 2 2 (0.05)
Device-related percutaneous site infection 0 0 1 1 (0.02)
Totals 151 119 (2.7) 99 88 (2.0)
*In patients who underwent sternotomy (n ¼ 3,891). †In patients who underwent ventricular assist device
implantation, re-implantation, or removed for heart transplantation (n ¼ 79).
CENTRAL ILLUSTRATION Average Cost Per Day in Patients With and
Without Infections
The noninfection group includes all patients from admission until the date of discharge or
the date of infection diagnosis. The infection group includes all patients who developed
infection from the diagnosis of infection to discharge. The distribution of expenses over
time was derived using the dates of the hospital charges during each hospitalization.
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19major infections were $37,513 for the entire cohort
and $39,264 when VAD and transplant recipients
were excluded (Table 3). ICU expenditures consti-
tuted almost one-half of the total incremental cost,
whereas hospital supplies, laboratory, and pharmacy
costs together contributed about one-third of the
extra cost (Figure 1).
COST OF REHOSPITALIZATIONS. In this cohort, 657
readmissions (15% of the index hospitalizations)
occurred within 30 days. Sixty of these readmissions
(9.1%) were attributed to major infections. Because
patients were monitored for a period of 60  5 days
after surgery, we were able to observe that the high
incidence of readmissions persisted beyond the con-
ventional 30-day cutoff. During the entire follow-up
period, after excluding rehabilitations and visits to
the emergency department, there were 849 read-
missions (19.7% of the index hospitalizations), of
which 545 (64%) were to the same hospital where the
initial surgery was done. Among these readmissions,
137 (16.1%) were infection related (including major
and minor infections, e.g., urinary tract infections
and superﬁcial wound infections), and 74 (8.7%) were
attributed to major HAIs alone. Readmissions due to a
major HAI had 2.6-fold higher costs than did read-
missions due to other causes, and their LOS was twice
the LOS of readmissions unrelated to a major HAI
(Table 4). Moreover, patients who had a major HAI
during the index hospitalization had a higher rate of
all-cause readmissions compared with that of pa-
tients who did not experience any major HAI at index
(33% vs. 20%). On the basis of the observed difference
in the rate of readmissions between these groups, we
estimated one extra readmission for every 10 major
HAIs developed during the index hospitalization. The
corresponding extra cost per major HAI at index is
reported in Table 4.
DISCUSSION
HAIs are a large impediment to achieving the full
beneﬁts of modern medicine in that they affect
1.7 million patients each year and are associated
with nearly 100,000 deaths in the U.S. (20). In cardiac
surgery patients, HAIs are the most common
noncardiac complication and have been associated
with increased morbidity and mortality, prolonged
hospitalizations, and higher costs (4,5). Over the past
decade, the ﬁeld of cardiac surgery has undergone
profound changes that have likely affected the bur-
dens, clinical and ﬁnancial, brought about by HAIs.
These changes have stimulated the need for ac-
curate, up-to-date evidence of such burdens. For
example, a general trend toward shorter LOS, and acorresponding shift of care toward nonacute care fa-
cilities and patients’ homes (21), have partially shifted
resource use to outpatient settings and readmissions.
Studies on the effects of HAI, however, have almost
exclusively focused on the index hospitalization,
analyzing, with only a few exceptions, the occurrence
of surgical-site infections after discharge (22,23).
Additionally, patients undergoing cardiac surgery are
increasingly older and affected by comorbidities such
as diabetes and obesity (24). These demographic and
TABLE 3 Mean Extra Costs and Length of Stay During Index Hospitalization
Patient Type
Cost, Median (95% CI), U.S. $ Length of Stay, Median (95% CI), Days
Median Unadjusted Mean Adjusted* Incremental Unadjusted Mean Adjusted* Incremental
VAD and transplantation included
No infection (n ¼ 4,201) 24,513 31,530 (30,654–32,407) Reference 9.4 (9.2–9.7) Reference
Infection (n ¼ 119) 83,833 110,155 (94,664–125,646) 37,513 (30,403–45,318) 33.4 (29.4–37.5) 14 (11–17)
VAD and transplantation excluded
No infection (n ¼ 4,108) 24,308 28,577 (27,980–29,174) Reference 8.9 (8.8–9.1) Reference
Infection (n ¼ 102) 73,268 93,363 (80,215–106,513) 39,264 (32,532–49,700) 30.0 (26.4–33.7) 14.1 (11.8–16.8)
*Adjusted using generalized linear model.
CI ¼ conﬁdence interval; VAD ¼ ventricular assist device implantation or explantation.
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20epidemiological changes, along with modiﬁcations of
appropriateness criteria (25,26), have reshaped the
characteristics of the patient population undergoing
cardiac surgery, and, therefore, the potential conse-
quences of HAIs on both clinical and economic
outcomes.
Among the type of major HAIs encountered in this
study, during both index hospitalizations and read-
missions, pneumonia was by far the most frequent
(48% of major HAIs), followed by bloodstreamtion of Incremental Costs, by Type of Resource Utilized
Others
9%
upplies
Medications
12%
ICU/CCU
47%
Room and
Board
5%
f resources were deﬁned by selected revenue code categories.
nit; ICU ¼ intensive care unit.infections (21%) (Table 2). These data are consistent
with other reports from cardiac surgery and from ICU
patients (4,27). Over the past decade, quality-
improvement efforts have gained ground against
HAIs such as catheter-associated bloodstream in-
fections and surgical-site infections (28,29). Given the
lack of standardization in making a diagnosis of
pneumonia, it is unclear how much progress has been
made toward a reduction in pneumonia-related HAIs
(30). Our results leave little doubt that pneumonia is
the HAI with the greatest economic impact in cardiac
surgery patients. The rigorous deﬁnition of HAIs in
general is crucial for valid comparisons across hospi-
tals and over time. All major HAIs in our study were
identiﬁed using CDC deﬁnitions and adjudicated by
an independent committee of infectious-diseases
experts. However, this level of monitoring and adju-
dication does not always reﬂect clinical decision
making. For example, a patient who was treated for
pneumonia may not have met the diagnostic criteria
for pneumonia. Therefore, by using stricter criteria in
this study than the criteria used for making clinical
decisions, the economic burden of HAIs in this study
may be a conservative estimate.
Our results show that the increases in LOS and cost
associated with major HAIs during the index hospi-
talization remain substantial. Our ﬁndings are
consistent with previous estimates of cost and LOS
reported for postoperative infection in coronary ar-
tery bypass graft patients and with the results of a
recent meta-analysis (5,15,31). However, they are
higher than the estimated upper bound of attribut-
able hospital cost due to major HAIs in the U.S.
inpatient population ($25,903 per major HAI [year-
2007 dollars]) (32).
Estimates of the incremental use of resources
associated with HAIs vary signiﬁcantly in published
reports (33,34). Such variations are partly a result of
the different settings and patient populations from
which data were collected and partly a result of the
TABLE 4 Mean Costs and Length of Stay of Readmission
Reason for Readmission
Costs, U.S. $ Length of Stay, Days
Of Readmission,
Mean (95% CI)
Due to HAI,
Mean
Of Readmission,
Mean (95% CI)
Due to HAI,
Mean
Infection 33,512 (20,903–46,121)
(n ¼ 52)
33,512* 11.5 (8.7–14.4)
(n ¼ 74)
11.5
Other 12,742 (10,488–14,996)
(n ¼ 493)
1,285† 6.0 (5.6–6.6)
(n ¼ 760)
0.6
The n values differ between cost and length of stay because cost data were available only for readmissions
within-network. *The entire cost of these readmissions is considered fully attributable to HAI. †Patients who had
an HAI during their index hospitalization were at an increased risk for all-cause readmissions. The corresponding
cost was calculated as Mean cost of readmissions not due to infection Number of extra readmissions due to HAI
at index/Number of HAI at index ¼ $12,742  0.1 ¼ $1,285.
CI ¼ conﬁdence interval; HAI ¼ health care–associated infection.
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Infections acquired in surgical settings, for example,
may have, on average, a greater impact on resource
utilization than do those acquired by medically
managed patients (35). Moreover, estimates from
single-center studies will reﬂect the local case mix
and practice of the center. The choice of statistical
methodology can also lead to signiﬁcant variation in
the estimates of HAI-attributable cost and LOS
(36–38). Regression analyses, such as GLM, are
commonly the preferred method of accounting for the
heterogeneity of a patient population. Matching
strategies, which control for confounders in the
design stage, rather than in the analysis stage, pre-
sent a tradeoff that is related to the number of vari-
ables used for matching data from infected patients
with those from noninfected controls (39). Too few
variables may be insufﬁcient to account for important
variation (bias from omitted variables), whereas more
variables may reduce the number of patients who can
be compared in the cohort (selection bias). Regression
models permit avoiding the selection bias that results
from the exclusion of unmatched cases and controls
while adjusting for a high number of confounders
(36,38,39).
Readmissions related to HAI are frequent and more
expensive than are non–HAI-related readmissions,
costing, on average, 2.7-fold more. As a result, the
cost of HAI-related readmissions represents about
one-third of the total cost attributable to HAIs.
Although there is evidence that higher readmission
rates may not be associated with worse outcomes
(and could even be associated with lower mortality),
readmissions have been recently targeted as an indi-
cator of presumed low-quality care that is associated
with high costs (40). In particular, the Centers
for Medicare and Medicaid Services now impose
ﬁnancial penalties on hospitals that have higher-
than-expected 30-day readmission rates (risk stan-
dardized) after treatment for acute myocardial
infarction, congestive heart failure, and pneumonia
(41). Beginning in ﬁscal year 2017, such penalties are
expected to include readmissions for patients un-
dergoing coronary artery bypass graft surgery (42).
The expansion of these policies will increase the
importance of HAI prevention in cardiac surgery pa-
tients (43,44).
STUDY LIMITATIONS. First, we captured only inpa-
tient costs. The economic burden on patients and
their families or other informal caregivers, as well as
treatments provided in the outpatient setting, are not
included. Second, cost data were available only for
readmissions to the same hospital, which represented
64% of all readmissions. It might be possible that thecost of readmissions to nonindex hospitals was sys-
tematically different from those of readmissions to
the same hospital, especially if the reason for change
was dictated by emergency, or if the readmitting
hospital lacked a cardiac surgery program, which
could potentially lead to costlier and inferior care.
However, the estimates of LOS, an important surro-
gate of resource utilization and reported in this
study, also include out-of-network hospitalizations.
Third, we did not examine the relationship between
HAI-associated costs and speciﬁc types of cardiac
procedures. However, the incremental cost and LOS
data generated for a cohort of patients that excludes
transplant and VAD recipients were not signiﬁcantly
different from those generated using the entire
cohort. This ﬁnding suggests that our estimates of
HAI-associated cost and LOS may be broadly appli-
cable to cardiac surgery patients. Finally, our choice
of model to adjust for measured confounders (GLM)
does not account for the time-dependent nature of
HAIs (45). However, GLM does allow for the adjust-
ment of those baseline variables that had been
measured in the observational study, which is an
advantage over multistate models that adjust exclu-
sively for time dependency (36,39).
CONCLUSIONS
This study identiﬁed the types of major HAIs in car-
diac surgery patients, the effects of these HAIs on
readmissions, and the utilization of speciﬁc hospital
resources. It supports the widely held belief that
reducing the enormous infection-related tolls of
mortality and morbidity is not only a clinical imper-
ative, but, especially in the current economic envi-
ronment, an economic necessity. Every major HAI,
on average, increases LOS by 2 weeks, adding
nearly $38,000 to the cost of the index hospitaliza-
tion. Moreover, readmissions associated with major
infections have an LOS twice as long as those of other
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Knowledge of
the costs of health care–associated infections can
align clinical and economic decisions to facilitate
efﬁcient, cost-effective health care.
TRANSLATIONAL OUTLOOK: Although consider-
able cost savings can accrue from the prevention of
health care–associated infections, additional research
is necessary to evaluate the cost-effectiveness of
various strategies of infection control.
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22readmissions (11.5 vs. 6.0 days), and cost nearly
threefold as much ($33,512 vs. $12,742). This study,
therefore, substantiates the economic argument for
preventive interventions and speciﬁes the possible
economic returns from such strategies. This in-
formation may help to drive quality-improvement
initiatives to reduce HAIs and ultimately improve
patient outcomes.
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